An Immunohistochemical Investigation of the Expression of Somatostatin Receptor Subtypes – Should Therapeutic Trials be Performed to Determine the Efficacy of Somatostatin Analogs in Treating Advanced Thyroid Malignances?

H. Pisarek; M. Pawlikowski; M. Marchlewska; R. Minias; K. Winczyk

doi:10.1055/s-0035-1548825

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2015; 123(06): 342-346
DOI: 10.1055/s-0035-1548825

Article

An Immunohistochemical Investigation of the Expression of Somatostatin Receptor Subtypes – Should Therapeutic Trials be Performed to Determine the Efficacy of Somatostatin Analogs in Treating Advanced Thyroid Malignances?

Authors

H. Pisarek

¹Department of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Poland
M. Pawlikowski

²Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Poland
M. Marchlewska

³Department of General and Endocrinological Surgery, Copernicus Memorial Hospital, Lodz, Poland
R. Minias

⁴Department of Pathomorphology and Clinical Cytopathology, Interfaculty Chair of Pathomorphology, Medical University of Lodz, Poland
K. Winczyk

¹Department of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Poland

Abstract

Somatostatin and its analogs through the specific receptor are known to demonstrate antiproliferative, anti-angiogenic and pro-apoptotic actions. The presence of SSTR-1–5 has not been sufficiently explored in poorly differentiated and undifferentiated thyroid tumors. The aim was to investigate the SSTR subtypes expression in these aggressive thyroid tumors. The study also discusses the usefulness of SSTR analogs as an alternative to conventional forms of therapy.

Methods: The analysis was performed by immunohistochemistry on the 14 archived poorly differentiated and 4 anaplastic thyroid carcinomas. A group of benign thyroid pathologies consisting of 11 patients was also included.

Results: SSTR-1, 2A, 2B, 3 and 5 were found to be expressed both in benign and malignant thyroid diseases, while SSTR-4 was not. Expression of SSTR-1 and SSTR-5 was found in samples with poorly differentiated thyroid tumors with a score of at least 2.0 being recorded in 10 tumors (71.4%). For SSTR-2A the same or higher score was noted in 5/14 (35.7%), for SSTR-2B in 4/14 (28.6%) and for SSTR-3 in 3/14 (21.4%) samples. SSTR-1, 2B and 5 were found to have a score of at least 2.0 in all undifferentiated thyroid tumors. Immunostaining of SSTR-2A and 3 was observed in 50% of samples. The immunopositive reactions were observed both in the membranes and cytoplasm of the thyroid cancer’ cells. In some cases positive immunostaining was localized also in the endothelium of intrathyroidal blood vessels.

Conclusions: The somatostatin multiligand analogs or selective agonists could be considered alternatives to conventional therapeutic agents in aggressive thyroid tumors.

Key words

aggressive thyroid carcinomas - somatostatin receptor subtypes - treatment modality

Full Text

References

References
1 Chiacchio S, Lorenzoni A, Boni G et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008; 33: 341-357
2 Smallridge RC, Ain KB, Asa SL et al. American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 2012; 22: 1104-1139
3 Sugitani I, Miyauchi A, Sugino K et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012; 36: 1247-1254
4 Taccaliti A, Silvetti F, Palmonella G et al. Anaplastic thyroid carcinoma. Front Endocrinol 2012; 3: 84
5 Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684
6 Krajewska J, Olczyk T, Roskosz J et al. Treatment with sorafenib in advanced thyroid cancer – a case report. Pol J Endocrinol 2010; 61: 492-496
7 Criel M, Geurs F. Remarkable Effect of Metronomic Chemotherapy in Diffuse Lung Metastases of Thyroid Cancer. J Thyroid Disord Ther 2012; 1: 101
8 Cabanillas ME, Sherman SI. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer 2012; 19: C19-C22
9 Prichard CN, Kim S, Yazici YD et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007; 117: 674-679
10 Mooney CJ, Nagaiah G, Fu P et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19: 233-240
11 Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787-2795
12 Weng JR, Chen CY, Pinzone JJ et al. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006; 13: 401-413
13 Antico-Arciuch VG, Russo MA, Dima M et al. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2: 1109-1126
14 Pawlikowski M, Kunert-Radek J, Stępień H. Somatostatin – an antiproliferative hormone. In: Progress in Neuropeptide Research. Dohler KD, Pawlikowski M. (eds.) Birkhauser Verlag; Basel: 1989: 3-12
15 Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008; 13: 822-840
16 Voltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003; 18: 601-609
17 Hu C, Yi C, Hao Z. The effect of somatostatin and SSTR 3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004; 3: 726-730
18 Theodoropoulou M, Stalla GK. Somatostatin receptors: From signaling to clinical practice. Front Neuroendocrinol 2013; 34: 228-252
19 Cozzi R, Montin M, Attanasio R et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91: 1397-1403
20 Farrall AJ, Ruffin M, Wetli-Hermosillo K et al. Long-term treatment of acromegaly with pasireotide (SOM230): results from a phase II extension study. Endocr Rev 2010; 31 (Suppl. 01) S856 (abst OR16-5)
21 Colao A, Petersenn S, Newell-Price J et al. 12-month phase 3 study of pasireotide in Cushing’s disease. N Eng J Med 2012; 366: 914-924
22 Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
23 Mato E, Matias-Guiu X, Chico A et al. Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 1998; 83: 2417-2420
24 Zatelli MC, Piccin D, Tagliati F et al. Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives. J Clin Endocrinol Metab 2006; 91: 2218-2224
25 Pawlikowski M. Somatostatin Receptors in Human Tumors – In Vitro Studies. In Somatostatin Analogs in Diagnostics and Therapy. Edited by Pawlikowski Marek. Landes Bioscience; 2007: 39-46
26 Pisarek H, Stępień T, Kubiak R et al. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res 2009; 2: 1
27 Klagge A, Krause K, Schierle K et al. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 2010; 42: 237-240
28 Atkinson H, England JA, Rafferty A et al. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 2013; 94: 226-229
29 Schulz S, Schulz St, Schmitt J et al. Immunocytochemical detection of somatostatin receptors SST1, SST2A and SST3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998; 4: 2047-2052
30 Pisarek H, Pawlikowski M, Kunert-Radek J et al. SSTR 1 and SSTR 5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 2010; 48: 142-147
31 Pisarek H, Krupiński R, Kubiak R et al. The different expression of somatostatin receptor subtypes – related genes and proteins in non-functioning and functioning adrenal cortex adenomas. Mol Med Reports 2011; 4: 963-969
32 Robbins RJ, Hill RH, Wang W et al. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000; 10: 177-183
33 Stokkel MP, Verkooijen RB, Bouwsma H et al. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer. Nucl Med Commun 2004; 25: 683-690
34 Teunissen JJ, Kwekkeboom DJ, Kooij PP et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 2005; 46 (Suppl. 01) 107S-114S
35 Budiawan H, Salavati A, Kulkarni H et al. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using ⁹⁰Yttrium and ¹⁷⁷Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2014; 4: 39-52
36 Hoelting T, Duh QY, Clark OH et al. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 1996; 81: 2638-2641
37 Gorges R, Kahaly G, Muller-Brand J et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11: 647-659
38 Waldherr C, Schumacher T, Pless M et al. Radiopeptide transmitted internal irradiation of non iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 2001; 22: 673-678
39 Kohlfuerst S, Igerc I, Gallowitsch HJ et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid 2006; 16: 1113-1119
40 Durán-Prado M, Saveanu A, Luque RM et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 2010; 95: 2497-2502
41 Duran-Prado M, Gahete MD, Hergueta-Redondo M. The new truncated somatostatin receptor variant sst5TMD4 is associated with poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2013; 31: 2049-2061
42 Puig-Domingo M, Luque RM, Reverter JL et al. The truncated isoform of somatostatin receptor 5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLOS ONE 2014; 9: 1-7
43 Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 (Suppl. 01) 67S-75S